Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

TPMT testing in rheumatology: any better than routine monitoring?

Payne K, Newman W, Fargher E, Tricker K, Bruce IN, Ollier WE.

Rheumatology (Oxford). 2007 May;46(5):727-9. Epub 2007 Jan 25. No abstract available.

PMID:
17255139
2.

Pharmacogenetics for the individualization of treatment of rheumatic disorders using azathioprine.

Seidman EG, Furst DE.

J Rheumatol. 2002 Dec;29(12):2484-7. Review. No abstract available.

PMID:
12465139
3.

Safety and efficacy of an intravenous loading dose of azathioprine for treatment of non-TPMT-deficient patients with rheumatic diseases.

Pickenpack A, Straub RH, Distler O, Hammond A, Oellerich M, Schölmerich J, Lang B, Schütz E.

Rheumatology (Oxford). 2000 Dec;39(12):1435-6. No abstract available.

PMID:
11136898
4.

Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription.

Fargher EA, Tricker K, Newman W, Elliott R, Roberts SA, Shaffer JL, Bruce I, Payne K.

J Clin Pharm Ther. 2007 Apr;32(2):187-95.

PMID:
17381669
5.

Single nucleotide polymorphism to disclose severe side-effects or proper dosage for each patient.

Ichikawa Y.

Intern Med. 2000 Jul;39(7):523-4. No abstract available.

6.

Outcome of patients on azathioprine: a need for a better pre-treatment assessment and dosing guideline.

Jabin D, Kumar S, Gow PJ.

N Z Med J. 2010 Oct 15;123(1324):67-73.

PMID:
20953224
7.
8.

TPMT testing before azathioprine therapy?

[No authors listed]

Drug Ther Bull. 2009 Jan;47(1):9-12. doi: 10.1136/dtb.2008.12.0033. Review.

PMID:
19129430
9.

Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.

Dilger K, Schaeffeler E, Lukas M, Strauch U, Herfarth H, Müller R, Schwab M.

Ther Drug Monit. 2007 Feb;29(1):1-5.

PMID:
17304143
10.

[Association between metabolic enzyme genotype of azathioprine and drug tolerance in patients with rheumatic diseases].

Zhan ZP, Liang LQ, Yang XY, Wang YX, Huang M, Li H.

Zhonghua Yi Xue Za Zhi. 2007 Jul 3;87(25):1734-7. Chinese.

PMID:
17919375
11.

Guidelines for prescribing azathioprine in dermatology.

Anstey AV, Wakelin S, Reynolds NJ; British Association of Dermatologists Therapy, Guidelines and Audit Subcommittee.

Br J Dermatol. 2004 Dec;151(6):1123-32. Review.

PMID:
15606506
12.

Role of thiopurine methyltransferase activity in the safety and efficacy of azathioprine in the treatment of pemphigus vulgaris.

Firooz A, Ghandi N, Hallaji Z, Chams-Davatchi C, Valikhani M, Karbakhsh Davari M.

Arch Dermatol. 2008 Sep;144(9):1143-7. doi: 10.1001/archderm.144.9.1143.

PMID:
18794458
13.

Azathioprine: when less is more.

Duley JA, Florin TH.

J Gastroenterol Hepatol. 2008 Sep;23(9):1317-9. doi: 10.1111/j.1440-1746.2008.05564.x. No abstract available.

PMID:
18853992
14.

The possible clinical application of pharmacogenetics in rheumatology.

Ferraccioli G.

J Rheumatol. 2003 Dec;30(12):2517-20. Review. No abstract available.

PMID:
14719186
15.

Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome.

Shah JA, Edwards CM, Probert CS.

Eur J Gastroenterol Hepatol. 2008 Mar;20(3):169-73. doi: 10.1097/MEG.0b013e3282f16d50.

PMID:
18301295
16.

[Biologics].

Kalden JR.

Z Rheumatol. 2016 Aug;75(6):604-10. doi: 10.1007/s00393-016-0122-2. Review. German. No abstract available. Erratum in: Z Rheumatol. 2016 Oct 11;:.

PMID:
27365024
17.

[Tapering and termination of immunosuppressive therapy].

Villiger PM, Müller-Ladner U.

Z Rheumatol. 2017 Feb;76(1):6-7. doi: 10.1007/s00393-016-0257-1. German. No abstract available.

PMID:
28097392
18.

Thiopurine-S-methyltransferase genotype and the response to azathioprine in inflammatory bowel disease.

Stocco G, Martelossi S, Decorti G, Bartoli F, Ventura A.

Aliment Pharmacol Ther. 2007 Oct 1;26(7):1083-4; author reply 1084-5. No abstract available.

19.
20.

Possible discontinuation of therapies in inflammatory rheumatic diseases - as with initiation of therapies, a shared decision between patient and rheumatologist.

Pincus T, Braun J, Kavanaugh A, Smolen JS.

Clin Exp Rheumatol. 2013 Jul-Aug;31(4 Suppl 78):S1-3. Epub 2013 Oct 3. No abstract available.

PMID:
24129127

Supplemental Content

Support Center